Precigen (NASDAQ:PGEN) is a biotechnology company focused on developing innovative gene and cell therapies to address unmet medical needs across multiple therapeutic areas. The company's operations encompass cutting-edge research and development activities aimed at creating next-generation treatments. Precigen's projects are spread across various stages of development, from pre-clinical investigations to advanced clinical trials, with a strong emphasis on oncology, autoimmune disorders, and infectious diseases. The objective of Precigen is to revolutionize healthcare by offering groundbreaking therapies that can significantly improve patient outcomes. Through its proprietary technology platforms and strategic collaborations, Precigen is dedicated to advancing its pipeline of therapeutic candidates towards commercialization, with the ultimate goal of delivering cutting-edge treatments to patients worldwide.